A phase I/II clinical trial (NCT04067336) is currently evaluating the safety and efficacy of Ziftomenib in patients with relapsed or refractory AML, including those with NPM1 mutations [35]. The gene discussed is NPM1; the disease is acute myeloid leukemia.